Results 81 to 90 of about 270,350 (354)

In‐hospital and 1 year incremental prognostic value of drug abuse detection in acute heart failure

ESC Heart Failure, EarlyView.
Abstract Aims The study aims to assess the in‐hospital and 1 year incremental prognostic value of recent drug abuse use, detected by a systematic urinary screening, in a consecutive cohort of patients hospitalized for acute heart failure (AHF). Methods All patients admitted for AHF with a drug abuse screening using a urinary assay were included in this
Charles Fauvel, Jean‐Guillaume Dillinger, Thomas Bochaton, Thomas Levasseur, Amine El Ouahidi, Cyril Zakine, Antony El Hadad, Nicolas Mansencal, Nathalie Noirclerc, Marc Goralski, Christophe Thuaire, Nathan Mewton, Guillaume Schurtz, Pascal Lim, Thibaut Pommier, Léo Lemarchand, Quentin Laissac, Nicolas Lamblin, Tanissia Boukertouta, Damien Logeart, Alain Cohen‐Solal, Patrick Henry, Théo Pezel, for the ADDICT‐ICCU Investigators, Victor Aboyans, Emeric Albert, Franck Albert, Sean Alvain, Nabil Amri, Stéphane Andrieu, Sabir Attou, Simon Auvray, Sonia Azzakani, Ruben Azencot, Marc Bedossa, Franck Boccara, Albert Boccara, Thomas Bochaton, Eric Bonnefoy‐Cudraz, Guillaume Bonnet, Nabil Bouali, Océane Bouchot, Claire Bouleti, Tanissia Boukertouta, Jean Baptiste Brette, Marjorie Canu, Aures Chaib, Clement Charbonnel, Anne Solene Chaussade, Alexandre Coppens, Yves Cottin, Arthur Darmon, Elena De Angelis, Clément Delmas, Laura Delsarte, Antoine Deney, Jean Claude Dib, Jean‐Guillaume Dillinger, Clemence Docq, Valentin Dupasquier, Meyer Elbaz, Antony El Hadad, Amine El Ouahidi, Nacim Ezzouhairi, Julien Fabre, Damien Fard, Charles Fauvel, Édouard Gerbaud, Martine Gilard, Marc Goralski, Nissim Grinberg, Alain Grentzinger, Marie Hauguel‐Moreau, Patrick Henry, Fabien Huet, Thomas Landemaine, Benoit Lattuca, Léo Lemarchand, Thomas Levasseur, Pascal Lim, Laura Maitre Ballesteros, Nicolas Mansencal, Benjamin Marie, David Martinez, Benoit Merat, Christophe Meune, Damien Millischer, Thomas Moine, Pascal Nhan, Nathalie Noirclerc, Patrick Ohlmann, Fabien Picard, Nicolas Piliero, Thibaut Pommier, Etienne Puymirat, Arthur Ramonatxo, Reza Rossanaly Vasram, François Roubille, Vincent Roule, Guillaume Schurtz, Mathilde Stevenard, David Sulman, Fédérico Swedsky, Victoria Tea, Eugénie Thevenet, Christophe Thuaire, Antonin Trimaille, Christophe Tron, Guillaume Viboud, Dominique Yomi, Cyril Zakine   +110 more
wiley   +1 more source

Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis

Journal of Nanobiotechnology
Background Cardiac fibrosis plays a critical role in the progression of various forms of heart disease, significantly increasing the risk of sudden cardiac death.
Xueli Zhao, Yuze Qin, Bowen Li, Yue Wang, Jiao Liu, Bo Wang, Jia Zhao, Jiaqi Yin, Lanlan Zhang, Jing Li, Junzhe Huang, Kun Chen, Liwen Liu, Yuanming Wu   +13 more
doaj   +1 more source

Hypertrophic cardiomyopathy: genetics and clinical perspectives.

Cardiovascular Diagnosis and Therapy, 2019
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and defined by unexplained isolated progressive myocardial hypertrophy, systolic and diastolic ventricular dysfunction, arrhythmias, sudden cardiac death and histopathologic ...
C. Wolf
semanticscholar   +1 more source

CARDIOMYOPATHY: The diagnosis of hypertrophic cardiomyopathy [PDF]

Heart, 2001
Although the pathology of hypertrophic cardiomyopathy (HCM) was first described by French pathologists in the mid 19th century, it remained for the virtually simultaneous reports of Brock and Teare in England some 43 years ago to bring modern attention to this fascinating entity.1 2 Subsequent to these surgical1 and pathological2 observations, there ...
openaire   +3 more sources

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

NRF2 signalling in cytoprotection and metabolism

British Journal of Pharmacology, EarlyView., 2023
The KEAP1‐NRF2 system plays a central role in cytoprotection in defence mechanisms against oxidative stress. The KEAP1‐NRF2 system has been regarded as a sulfur‐utilizing cytoprotective mechanism, because KEAP1 serves as a biosensor for electrophiles by using its reactive thiols and NRF2 is a transcriptional factor regulating genes involved in sulfur ...
Shohei Murakami, Yusuke Kusano, Keito Okazaki, Takaaki Akaike, Hozumi Motohashi   +4 more
wiley   +1 more source

HYPERTROPHIC CARDIOMYOPATHY: GENETIC ALTERATIONS, PATHOGENESIS AND PATHOPHYSIOLOGY

Российский кардиологический журнал, 2014
The review is dedicated to the description of genetic alterations, pathogenetic mechanisms and pathophysiology of hypertrophic cardiomyopathy, based on the analysis of current up to date information.
N. T. Vatutin, G. G. Taradin, M. S. Maron   +2 more
doaj   +1 more source

Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.

Journal of the American College of Cardiology, 2022
B. Maron, M. Desai, R. Nishimura, P. Spirito, H. Rakowski, J. Towbin, E. Rowin, M. Maron, M. Sherrid   +8 more
semanticscholar   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.

Journal of the American College of Cardiology, 2022
M. Desai, A. Owens, J. Geske, K. Wolski, S. Naidu, N. Smedira, P. Cremer, H. Schaff, E. McErlean, Christina Sewell, Wanying Li, Lulu Sterling, K. Lampl, J. Edelberg, A. Sehnert, S. Nissen   +15 more
semanticscholar   +1 more source